BUFFALO, N.Y., Sept. 15 /PRNewswire/ -- Kinex Pharmaceuticals announced
that David Hsia, Ph.D. has been appointed to the Company's Board of
Dr. Hsia is a pharmaceutical veteran. He is a co-founder of Watson
Pharmaceuticals, a publicly traded company listed in New York Stock
Exchange (ticker: WPI). He was formerly Senior Vice President, Scientific
Affairs of Watson Pharmaceuticals before his retirement. He has been
involved in the development of various pharmaceutical formulations for over
twenty years. Dr. Hsia received a Ph.D. in Industrial and Physical Pharmacy
from Purdue University in 1975.
"Dr. Hsia is well known for his expertise in pharmaceutical development
in our industry," commented Dr. Allen Barnett, Chief Executive Officer of
Kinex Pharmaceuticals. "As the Company moves forward, we look forward to
leveraging the full breadth of David's expertise as a Board member to
assist us in developing our new drug candidates," Commented Dr. Johnson
Lau, Executive Chairman of the Board.
"I am delighted to have a chance to work with the team at Kinex. The
company's pipeline is very strong and I am glad to have this opportunity to
assist to further advance their product pipeline," commented Dr. Hsia.
About Kinex Pharmaceuticals
Kinex is a drug discovery and development company that is focused on
the use of its platform technology and compound libraries to identify and
develop peptide-competitive kinase inhibitors. The Company's clinical
compound KX2-391 is a selective Src kinase inhibitor that is currently in
Phase 1 trials for oncology. Kinex's pipeline is focused on selective
inhibitors for kinase targets that are important in oncology and
inflammation and immunology. The Company is located in the New York State
Center of Excellence in Bioinformatics and Life Sciences, on the Buffalo
Niagara Medical Campus in Buffalo, New York.
SOURCE Kinex Pharmaceuticals